Strategy acquired 1,036 Bitcoin for about $81.9 million, pushing its total holdings above 850,000 BTC, representing over 4% of Bitcoin's max supply. The purchase was funded by selling shares of its Class A stock, while also repurchasing preferred shares and maintaining substantial cash reserves. Europe's largest asset manager, Amundi, increased its investment in Strategy by 43.7%, adding institutional support. This move highlights Strategy's ongoing commitment to Bitcoin as its primary reserve asset, though its Bitcoin holdings currently trade slightly below their average acquisition cost, creating an unrealized loss. Investors will watch how Strategy balances Bitcoin accumulation, share repurchases, and cash reserves amid market price fluctuations.
The strategy's Bitcoin holdings now exceed 850,000 BTC, representing over 4% of Bitcoin's maximum supply. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Nov 09, 2026 21:02 WIB: out of 50 major cryptocurrencies, 19 rose and 29 fell. Ethereum (ETH) traded at Rp38.308.227 with a 1-day change of -5.23% and a typical hold time on Pluang of 108 days, while Zilliqa (ZIL) rose 4.52% to Rp31 with 74% sell order activity, and Basic Attention Token (BAT) increased 4.07% to Rp2.291 with 79% buy order activity.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
